Abcam Dividends - ABC

Abcam Dividends - ABC

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Abcam Plc ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change Price Change % Stock Price High Price Low Price Open Price Close Price Last Trade
  19.00 1.65% 1,169.00 1,171.00 1,141.00 1,146.00 1,150.00 14:51:18
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Abcam ABC Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
09/09/2019FinalGBX8.5830/06/201830/06/201907/11/201908/11/201929/11/201912.13
04/03/2019InterimGBX3.5530/06/201830/06/201914/03/201915/03/201912/04/20190
11/09/2018FinalGBX8.5830/06/201730/06/201808/11/201809/11/201830/11/201812
05/03/2018InterimGBX3.4230/06/201730/06/201815/03/201816/03/201812/04/20180
11/09/2017FinalGBX7.3530/06/201630/06/201716/11/201717/11/201708/12/201710.18
06/03/2017InterimGBX2.82530/06/201630/06/201716/03/201717/03/201713/04/20170
12/09/2016FinalGBX6.5630/06/201530/06/201610/11/201611/11/201602/12/20168.91
07/03/2016InterimGBX2.3530/06/201530/06/201617/03/201618/03/201615/04/20160
14/09/2015FinalGBX5.9230/06/201430/06/201512/11/201513/11/201504/12/20158.21
09/03/2015InterimGBX2.2930/06/201430/06/201519/03/201520/03/201517/04/20150
09/09/2014FinalGBX5.6230/06/201330/06/201405/11/201407/11/201428/11/20147.75
04/03/2014InterimGBX2.1330/06/201330/06/201419/03/201421/03/201418/04/20140
10/09/2013FinalGBX5.130/06/201230/06/201306/11/201308/11/201329/11/20137.04
05/03/2013InterimGBX1.9430/06/201230/06/201320/03/201322/03/201319/04/20130
06/09/2012FinalGBX4.3630/06/201130/06/201231/10/201202/11/201223/11/20126.05
05/03/2012InterimGBX1.6930/06/201130/06/201221/03/201223/03/201220/04/20120
13/09/2011FinalGBX3.830/06/201030/06/201102/11/201104/11/201125/11/20115.25
08/03/2011InterimGBX1.4530/06/201030/06/201116/03/201118/03/201115/04/20110
07/09/2010FinalGBX14.6130/06/200930/06/201003/11/201005/11/201026/10/201120.03
09/03/2010InterimGBX5.4230/06/200930/06/201017/03/201019/03/201001/04/20100
08/09/2009FinalGBX9.430/06/200830/06/200904/11/200906/11/200927/11/200912.11
09/09/2008FinalGBX4.5630/06/200730/06/200805/11/200807/11/200828/11/20085.6
01/10/2007FinalGBX3.1930/06/200630/06/200707/11/200709/11/200707/12/20073.99
19/02/2007InterimGBX0.831/12/200531/12/200607/04/200709/04/200709/03/20070
05/09/2006FinalGBX230/06/200530/06/200625/10/200627/10/200624/11/20062.7
14/02/2006InterimGBX0.701/07/200531/12/200508/03/200610/03/200607/04/20060

Top Dividend Posts

DateSubject
10/9/2019
11:23
mw8156: significant fall in the share price might result in it being taken over as the leading antibody company, their cash generative nature and their huge catalogue of 18000 validated antibodies and that would be Britain's only leading life sciences tools company disappearing which would be a shame after Illumina snapped up our sequencing technology.
09/9/2019
08:37
erogenous jones: City did not like the figures. Sharp rises and sharp falls (in the share price) are normal for this company.
05/3/2019
15:26
erogenous jones: Not in the least fussed about the drop yesterday, or the rise today, for that matter. Good, well managed and profitable company that has a track record of share price growth over many years. That was the case last week and remains the case this week. My average price is £6.50 and until the company ceases to be as profitable as in previous years I see no reason why I should not allow profits to run.
12/12/2018
16:05
investorschampion: Milner's wife recently bought £2m worth of shares. It's a nice confidence booster following the recent share price weakness, but perhaps some executive directors should follow suit? hxxps://www.investorschampion.com/channel/blog/follow-the-directors-whos-buying
07/12/2018
11:31
jurgenklopp: With regards to the large PDMR purchase yesterday it should be noted that Milner sold over 1 million shares at £14.41 as recently as late September. However re-investing 2 million quid back in company shares ought to provide some kind of support to the share price in these strange times !!
03/11/2016
11:09
shawzie: I can only agree with Panmure that the current share price overvalues this Company. Earnings fairly static on increasing turnover. Intangibles increasing rapidly, but not reflected in increased earnings. Increase in Net Worth of Company due mainly to increase in Intangibles. Does anyone have a more optimistic view?
25/1/2016
11:48
campbed: Very good trading update today outlining progress on all fronts. A great British success story . Share price at 640p almost back to the all time high of 660p reached at end of 2015 before the market-wide Jan sell off.
31/1/2015
10:42
apad: Slater in the Telegraph today - with any luck that should drive the share price down for those who are looking for an entry point. apad  . .R01;and some can be disastrous Other Aim shares that are favourites of veteran IHT investors are Young & Co’s Brewery, Advanced Medical Solutions and Abcam. All three are good sound companies but it seems to me that their share prices are living on the memory of their excellent past growth. Nowadays their p/e ratios are in or around the 20s with only single-digit earnings growth forecast. They are not for me because the slightest upset in their earnings growth could cause a major setback in their shares.
22/1/2015
17:43
jeffcranbounre: Abcam is featured in today's ADVFN podcast. To listen to the podcast click here> http://bit.ly/ADVFN0113 In today's podcast: - Chris Oil, financial writer and city investor will be chatting about a well known name who could be back in fashion. Chris on Twitter is @ChrisOil - And Rodney Hobson, a financial speaker, writer and author of investment books including Shares Made Simple, the beginner's guide to the stock market. Rodney on Twitter is @RodneyHobson - The micro and macro news - Plus the broker forecasts Every Tuesday is Ten Bagger Tuesday on the podcast. If you know of a stock, whose share price has the potential to increase ten fold, just click the link below. Ten Bagger Tuesday (All it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). Once a week, on a Friday, I feature a tip from a listener to this podcast, if you'd like to suggest a stock click the link below: Suggest a stock (Again all it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). You can subscribe to this podcast in iTunes by clicking HERE To follow me on Twitter click HERE As a listener to the ADVFN podcast you can take advantage of some exclusive first year discounts on popular subscriptions: Bronze - £50 (normally £73.82/year) Silver - £145 (normally £173.71/year) Level 2 - £350 (normally £472.94/year) Call 0207 0700 961 and ask for the ADVFN Podcast discount to take advantage of these reduced rates or just CLICK HERE for more information. Please DO NOT buy any stock recommended in this podcast basely solely on what you hear. The opinions in this podcasts are just that, opinions. Please do you own research before investing. Justin    
20/5/2014
07:56
simon gordon: Unicorn AIM VCT - 20/5/14 Abcam (-23%) is a global leader in the supply of innovative protein research tools. In March 2014, Abcam released its financial results for the six month period ended 31 December 2013, which were in line with your Investment Manager's internal forecasts. Revenues of £61.9m (H2 2012: £57.3m) represented half-year on half-year growth of over 8%, while earnings per share were up 6.5% to 8.74p (H2 2012: 8.21p). Abcam remains a cash generative business with a robust balance sheet. Net cash balances at the period end amounted to £35.3m. Despite Abcam's many obvious qualities, market reaction to the release of Interim Results in early March was negative as investors worried about currency headwinds and the impact of possible cuts to health budgets in the key North American market, which accounts for 43% of total sales. As a result, Abcam's share price ended the period markedly lower. The holding has been retained in the portfolio in the expectation that the de-rating in the value of Abcam will prove to be temporary.
Your Recent History
LSE
ABC
Abcam
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191017 14:10:39